These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 21479093)

  • 21. Risk of cardiovascular events in patients at optimal values for combined lipid parameters.
    Stanek EJ; Sarawate C; Willey VJ; Charland SL; Cziraky MJ
    Curr Med Res Opin; 2007 Mar; 23(3):553-63. PubMed ID: 17357251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polypill and global cardiovascular health strategies.
    Sanz G; Fuster V
    Semin Thorac Cardiovasc Surg; 2011; 23(1):24-9. PubMed ID: 21807295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Burden of First and Recurrent Cardiovascular Events Among Patients With Hyperlipidemia.
    Punekar RS; Fox KM; Richhariya A; Fisher MD; Cziraky M; Gandra SR; Toth PP
    Clin Cardiol; 2015 Aug; 38(8):483-91. PubMed ID: 26100722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country.
    Conen D; Wietlisbach V; Bovet P; Shamlaye C; Riesen W; Paccaud F; Burnier M
    BMC Public Health; 2004 Mar; 4():9. PubMed ID: 15043756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
    Roshandel G; Khoshnia M; Poustchi H; Hemming K; Kamangar F; Gharavi A; Ostovaneh MR; Nateghi A; Majed M; Navabakhsh B; Merat S; Pourshams A; Nalini M; Malekzadeh F; Sadeghi M; Mohammadifard N; Sarrafzadegan N; Naemi-Tabiei M; Fazel A; Brennan P; Etemadi A; Boffetta P; Thomas N; Marshall T; Cheng KK; Malekzadeh R
    Lancet; 2019 Aug; 394(10199):672-683. PubMed ID: 31448738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
    Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
    Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The epidemiologic transition to chronic diseases in developing countries: cardiovascular mortality, morbidity, and risk factors in Seychelles (Indian Ocean). Investigators of the Seychelles Heart Study.
    Bovet P
    Soz Praventivmed; 1995; 40(1):35-43. PubMed ID: 7900434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipid-lowering for prevention of coronary heart disease: what policy now?
    Ul Haq I; Ramsay LE; Pickin DM; Yeo WW; Jackson PR; Payne JN
    Clin Sci (Lond); 1996 Oct; 91(4):399-413. PubMed ID: 8983865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective?
    Sigvant B; Henriksson M; Lundin F; Wahlberg E
    Eur J Cardiovasc Prev Rehabil; 2011 Apr; 18(2):254-61. PubMed ID: 21450673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study.
    Barrios V; Kaskens L; Castellano JM; Cosin-Sales J; Ruiz JE; Zsolt I; Fuster V; Gracia A
    Rev Esp Cardiol (Engl Ed); 2017 Jan; 70(1):42-49. PubMed ID: 27474481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The cardiovascular risk factor profiles among end-stage renal failure patients treated with continuous ambulatory peritoneal dialysis and intermittent hemodialysis.
    Zamiah SAKS; Draman CR; Seman MR; Safhan AF; Rozalina R; Nik Ruzni NI
    Saudi J Kidney Dis Transpl; 2018; 29(1):114-119. PubMed ID: 29456216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The polypill: An effective approach to increasing adherence and reducing cardiovascular event risk.
    Bramlage P; Sims H; Minguet J; Ferrero C
    Eur J Prev Cardiol; 2017 Feb; 24(3):297-310. PubMed ID: 27798363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cardiovascular disease situation in Seychelles.
    Hungerbuhler P; Bovet P; Shamlaye C
    World Health Stat Q; 1993; 46(2):108-12. PubMed ID: 8303904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial.
    Singh K; Crossan C; Laba TL; Roy A; Hayes A; Salam A; Jan S; Lord J; Tandon N; Rodgers A; Patel A; Thom S; Prabhakaran D
    Int J Cardiol; 2018 Jul; 262():71-78. PubMed ID: 29622506
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK.
    Danese MD; Gleeson M; Kutikova L; Griffiths RI; Azough A; Khunti K; Seshasai SR; Ray KK
    BMJ Open; 2016 Aug; 6(8):e011805. PubMed ID: 27496237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease.
    Jowett S; Barton P; Roalfe A; Fletcher K; Hobbs FDR; McManus RJ; Mant J
    PLoS One; 2017; 12(9):e0182625. PubMed ID: 28873416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implications of scaling up cardiovascular disease treatment in South Africa: a microsimulation and cost-effectiveness analysis.
    Basu S; Wagner RG; Sewpaul R; Reddy P; Davies J
    Lancet Glob Health; 2019 Feb; 7(2):e270-e280. PubMed ID: 30528531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of cardiovascular risk factors, events, and costs across four BMI categories.
    Brixner DI; Bron M; Bellows BK; Ye X; Yu J; Raparla S; Oderda GM
    Obesity (Silver Spring); 2013 Jun; 21(6):1284-92. PubMed ID: 23913737
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.